Cardiovascular applications of hyperpolarized contrast media and metabolic tracers

Experimental Biology and Medicine

Volumn 234, Issue 12, 2009, Pages 1395-1416

  Bhattacharya, Pratip ^a   Ross, Brian D ^a   Bünger, Rolf ^b  

^a HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

Cardiovascular; DNP; Hyperpolarization; Imaging; Metabolism; Pasadena

Indexed keywords

ALANINE; CARBON 14; CONTRAST MEDIUM; LACTIC ACID; PYRUVIC ACID; TRACER;

CARDIOVASCULAR DISEASE; DECARBOXYLATION; GLYCOLYSIS; HUMAN; HYPERPOLARIZATION; METABOLISM; NONHUMAN; PROTEIN DEGRADATION; SHORT SURVEY;

ANIMALS; CARBON RADIOISOTOPES; CONTRAST MEDIA; GLYCOLYSIS; HUMANS; MAGNETIC RESONANCE IMAGING; OXIDATION-REDUCTION; PYRUVIC ACID; RADIOACTIVE TRACERS; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 72449158801     PISSN: 15353702     EISSN: 15353699     Source Type: Journal    
DOI: 10.3181/0904-MR-135     Document Type: Short Survey

References (102)

1. Bing RJ. The metabolism of the heart. Harvey Lect 50:27-70, 1955.
2. Edelman R, Hesselink J, Zlatkin M. Clinical Magnetic Resonance Imaging. Philadelphia: W. B. Saunders and Co., 1996.
3. Hove MT, Neubauer S. Evaluating metabolic changes in heart disease by magnetic resonance spectroscopy. Heart Metab 32:18-21, 2006. (Pubitemid 44690927)
4. Orenstein BW. Ultra high-field MRI - the pull of big magnets. Radiology Today 7:10, 2006.
5. Bowers CR, Weitekamp DP. Transformation of symmetrization order to nuclear-spin magnetization by chemical-reaction and nuclear-magnetic-resonance. Phys Rev Lett 57:2645-2648, 1986.
6. Golman K, Ardenkjaer-Larsen JH, Petersson JS, Mansson S, Leunbach I. Molecular imaging with endogenous substances. Proc Natl Acad Sci U S A 100:10435-10439, 2003.
7. Happer W, Miron E, Schaefer S, Schreiber D, Vanwijngaarden WA, Zeng X. Polarization of the nuclear spins of noble-gas atoms by spin exchange with optically pumped alkali-metal atoms. Phys Rev A 29:3092-3110, 1984.
8. Cherubini A, Payne GS, Leach MO, Bifone A. Hyperpolarising C-13 for NMR studies using laser-polarised Xe-129: SPINOE vs thermal mixing. Chem Phys Lett 371:640-644, 2003. (Pubitemid 36379721)
9. Biskup N, Kalechofsky N, Candela D. Spin polarization of xenon films at low-temperature induced by 3He. Physica B Condensed Matter 329-333:437-438 2003.
10. Bowers CR, Weitekamp DP. Para-hydrogen and synthesis allow dramatically enhanced nuclear alignment. J Am Chem Soc 109:5541-5542, 1987.
11. Goldman M, Johannesson H, Axelsson O, Karlsson M. Hyperpolarization of C-13 through order transfer from parahydrogen: a new contrast agent for MRI. J Magn Reson Imaging 23:153-157, 2005. (Pubitemid 40503892)
12. Goldman M, Johannesson H, Axelsson O, Karlsson M. Design and implementation of C-13 hyperpolarization from para-hydrogen, for new MRI contrast agents. Comptes Rendus Chimie 9:357-363, 2006.
13. Hövener JB, Chekmenev EY, Harris KC, Perman WH, Robertson LW, Ross BD, Bhattacharya P. PASADENA hyperpolarization of 13C biomolecules: equipment design and installation. MAGMA 22:111-121, 2009.
14. Bhattacharya P, Harris K, Lin AP, Mansson M, Norton VA, Perman WH, Weitekamp DP, Ross BD. Ultra-fast three dimensional imaging of hyperpolarized C-13 in vivo. MAGMA 18:245-256, 2005. (Pubitemid 41742188)
15. Johansson E, Olsson LE, Mansson S, Petersson JS, Golman K, Stahlberg F, Wirestam R. Perfusion assessment with bolus differentiation: a technique applicable to hyperpolarized tracers. Magn Reson Med 52:1043-1051, 2004. (Pubitemid 39453277)
16. Mansson S, Johansson E, Magnusson P, Chai CM, Hansson G, Petersson JS, Stahlberg F, Golman K. 13C imaging - a new diagnostic platform. Eur Radiol 16:57-67, 2006. (Pubitemid 43103569)
17. Chekmenev EY, Chow S-K, Tofan D, Weitekamp DP, Ross BD, Bhattacharya P. Fluorine-19 NMR chemical shift probes molecular binding to lipid membranes. J Phys Chem B 112:6285-6287, 2008.
18. Abragam A, Goldman M. Principles of dynamic nuclear-polarization. Rep Prog Phys 41:395-467, 1978.
19. Day S, Kettunen MI, Gallagher FA, Hu DE, Lerche M, Wolber J, Golman K, Ardenkjaer-Larsen JH, Brindle KH. Detecting tumor response to treatment using hyperpolarized 13C magnetic resonance imaging and spectroscopy. Nat Med 13:1382-1387, 2007. (Pubitemid 350073590)
20. Bunger R, Mallet RT. Mitochondrial pyruvate transport in working guinea-pig heart. Work-related vs. carrier-mediated control of pyruvate oxidation. Biochim Biophys Acta 1151:223-236, 1993.
21. Garland PB, Newsholme EA, Randle PJ. Regulation of glucose uptake by muscle: effects of fatty acids and ketone bodies and of alloxan-dia. Biochem J 93:665, 1964.
22. Olson MS, Dennis SC, DeBuysers MS, Padma A. The regulation of pyruvate dehydrogenase in the isolated perfused rat heart. J Biol Chem 25:7369-7375, 1978. (Pubitemid 9045221)
23. Wieland O, Funcke HV, Loffler G. Interconversion of pyruvate dehydrogenase in rat heart muscle upon perfusion with fatty acids or ket. FEBS Lett 15:295-298, 1971.
24. Sundqvist KE, Peuhkurinen KJ, Hiltunen JK, Hassinen IE. Effect of acetate and octanoate on tricarboxylic acid cycle metabolite disposal during propionate oxidation in the perfused rat heart. Biochim Biophys Acta 801:429-436, 1984.
25. Taylor SI, Mukherjee C, Jungas RL. Regulation of pyruvate dehydrogenase in isolated rat liver mitochondria. Effects of octanoate, oxidation-reduction state, and adenosine triphosphate to adenosine diphosphate ratio. J Biol Chem 250:2028-2035, 1975.
26. Bunger R. Compartmented pyruvate in perfused working heart. Am J Physiol 249:H439-449, 1985.
27. Assimacopoulos-Jeannet F, McCormack JG, Jeanrenaud B. Effect of phenylephrine on pyruvate dehydrogenase activity in rat hepatocytes and its interaction with insulin and glucagon. FEBS Lett 159:83-88, 1983.
28. Panchal AR, Comte B, Huang H, Dudar B, Roth B, Chandler M, Des Rosiers C, Brunengraber H, Stanley WC. Acute hibernation decreases myocardial pyruvate carboxylation and citrate release. Am J Physiol Heart Circ Physiol 281:H1613-1620, 2001. (Pubitemid 33774398)
29. Kobayashi K, Neely JR. Effects of ischemia and reperfusion on pyruvate dehydrogenase activity in isolated rat hearts. J Mol Cell Cardiol 15:359-367, 1983.
30. Garland PB, Newsholm EA, Randle PJ. Effect of fatty acids ketone bodies diabetes and starvation on pyruvate metabolism in rat heart an. Nature 195:381-383, 1962.
31. Wieland O, Siess E. Interconversion of phospho- and dephosphoforms of pig heart pyruvate dehydrogenase. Proc Natl Acad Sci U S A 65:947-954, 1970.
32. Portenhauser R, Wieland O. Regulation of pyruvate dehydrogenase in mitochondria of rat liver. Eur J Biochem 31:308-314, 1972.
33. Siess EA, Wieland OH. Regulation of pyruvate dehydrogenase interconversion in isolated hepatocytes by the mitochondrial ATP/ADP ratio. FEBS 52:226-230, 1975.
34. Wieland OH, Siess EA, Weiss L, Loffler G, Patzelt C, Portenhauser R, Hartmann U, Schirmann A. Regulation of the mammalian pyruvate dehydrogenase complex by covalent modification. Symp Soc Exp Biol 27:371-400, 1973.
35. Hutson NJ, Kerbey AL, Randle PJ, Sugden PH. Regulation of pyruvate dehydrogenase by insulin action. Prog Clin Biol Res 31:707-719, 1979.
36. Kerbey AL, Randle PJ, Cooper RH, Whitehouse S, Pask HT, Denton RM. Regulation of pyruvate dehydrogenase in rat heart. Mechanism of regulation of proportions of dephosphorylated and phosphorylated enzyme by oxidation of fatty acids and ketone bodies and of effects of diabetes: role of coenzyme A, acetyl-coenzyme A and reduced and oxidized nicotinamide-adenine dinucleotide. Biochem J 154:327-348, 1976.
37. Jahania M, Kristo G, Niu X, Yoshimura Y, Bunger R, Lasley RD, Mentzer RMJ. Pyruvate reduces both myocardial stunning and infarct size in an in-vivo model of regional myocardial ischemia. American College of Surgeons (Abstract), 2003.
38. Braunwald E, Kloner RA. The stunned myocardium: prolonged postischemic ventricular dysfunction. Circulation 66:1146-1149, 1982. (Pubitemid 13238825)
39. Kitakaze M, Weisfeldt M, Marban E. Acidosis during early reperfusion prevents myocardial stunning in perfused ferret hearts. J Clin Invest 82:920-927, 1988. (Pubitemid 18228349)
40. Bolli R, Marban E. Molecular and cellular mechanisms of myocardial stunning. Physiol Rev 79:609-634, 1999. (Pubitemid 29210931)
41. Mentzer RMJ, Van Wylen DG, Sodhi J, Weiss RJ, Lasley RD, Willis J, Bunger R, Habil, Flint LM. Effect of pyruvate on regional ventricular function in normal and stunned myocardium. Ann Surg 209:629-633; discussion 633-1624, 1989.
42. Atar D, Gao WD, Marban E. Alterations of excitation-contraction coupling in stunned myocardium and in failing myocardium. J Mol Cell Cardiol 27:783-791, 1995.
43. Gao WD, Atar D, Backx PH, Marban E. Relationship between intracellular calcium and contractile force in stunned myocardium. Direct evidence for decreased myofilament Ca2+ responsiveness and altered diastolic function in intact ventricular muscle. Circ Res 76:1036-1048, 1995.
44. Bunger R, Mallet RT, Hartman DA. Pyruvate-enhanced phosphorylation potential and inotropism in normoxic and postischemic isolated working heart. Near-complete prevention of reperfusion contractile failure. Eur J Biochem 180:221-233, 1989. (Pubitemid 19080479)
45. Golman K, Petersson JS, Magnusson P, Johansson E, Akeson P, Chai CM, Hansson G, Mansson S. Cardiac metabolism measured non-invasively by hyperpolarized 13C MRI. Magn Reson Med 59:1005-1013, 2008. (Pubitemid 351590513)
46. Mallet RT, Hartman DA, Bunger R. Glucose requirement for postischemic recovery of perfused working heart. Eur J Biochem 188:481-493, 1990. (Pubitemid 20106264)
47. Golman K, Olsson LE, Axelsson O, Mansson S, Karlsson M, Petersson JS. Molecular imaging using hyperpolarized 13C. Br J Radiol 76 Spec No 2:S118-127, 2003. (Pubitemid 39530305)
48. Bunger R, Glanert S, Sommer O, Gerlach E. Inhibition by (aminooxy) acetate of the malate-aspartate cycle in the isolated working guinea pig heart. Hoppe Seylers Z Physiol Chem 361:907-914, 1980. (Pubitemid 11235564)
49. LaNoue KF, Williamson JR. Interrelationships between malate-aspartate shuttle and citric acid cycle in rat heart mitochondria. Metabolism 20:119-140, 1971.
50. Safer B, Williamson JR. Functional significance of the malate-aspartate shuttle for the oxidation of cytoplasmic reducing eq. Myocardiology 1:34-43, 1972.
51. Safer B. The metabolic significance of the malate-aspartate cycle in heart. Circ Res 37:527-533, 1975.
52. Safer B, Smith CM, Williamson JR. Control of the transport of reducing equivalents across the mitochondrial membrane in perfused rat heart. J Mol Cell Cardiol 2:111-124, 1971.
53. Sharma N, Okere IC, Brunengraber DZ, McElfresh TA, King KL, Sterk JP, Huang H, Chandler MP, Stanley WC. Regulation of pyruvate dehydrogenase activity and citric acid cycle intermediates during high cardiac power generation. J Physiol 562:593-603, 2005.
54. Panchal AR, Comte B, Huang H, Kerwin T, Darvish A, des Rosiers C, Brunengraber H, Stanley WC. Partitioning of pyruvate between oxidation and anaplerosis in swine hearts. Am J Physiol Heart Circ Physiol 279:H2390-2398, 2000.
55. Pettit FH, Reed LJ. Pyruvate dehydrogenase complex from bovine kidney and heart. Methods Enzymol 89 Pt D:376-386, 1982.
56. Kerbey AL, Radcliffe PM, Randle PJ, Sugden PH. Regulation of kinase reactions in pig heart pyruvate dehydrogenase complex. Biochem J 181:427-433, 1979. (Pubitemid 9238812)
57. Pettit FH, Pelley JW, Reed LJ. Regulation of pyruvate dehydrogenase kinase and phosphatase by acetyl-CoA/CoA and NADH/NAD ratios. Biochem Biophys Res Comm 65:575-582, 1975.
58. Bunger R, Permanetter B, Sommer O, Yaffe S. Adaptive changes of pyruvate oxidation in perfused heart during adrenergic stimulation. Am J Physiol 242:H30-36, 1982.
59. Bunger R, Sommer O, Walter G, Stiegler H, Gerlach E. Functional and metabolic features of an isolated perfused guinea pig heart performing pressure-volume work. Pflugers Arch 380:259-266, 1979. (Pubitemid 9209100)
60. Bunger R, Soboll S, Permanetter B. Effects of norepinephrine on coronary flow, myocardial substrate utilization, and subcellular adenylates. Ca2+ Entry Blockers, Adenosine, and Neurohumors. Baltimore/Munich: Urban & Schwarzenberg, pp267-279, 1983.
61. Bunger R, Haddy FJ, Querengasser A, Gerlach E. An isolated guinea pig heart preparation with in vivo like features. Pflugers Arch 353:317-326, 1975.
62. Bunger R, Permanetter B, Sommer O. Pyruvate oxidation in the hemoglobin-free perfused guinea pig heart: effects of pressure, work and noradrenaline. Microcirculation of the Heart. Berlin/Heidelberg: Springer Verlag, pp126-135, 1982.
63. Bunger R, Permanetter B, Yaffe S. Energy utilization and pyruvate as determinants of pyruvate dehydrogenase in norepinephrine-stimulated heart. Pflugers Arch 397:214-219, 1983.
64. Bunger R, Permanetter B. Parallel stimulation by Ca2+ of inotropism and pyruvate dehydrogenase in perfused heart. Am J Physiol 247:C45-52, 1984.
65. Wieland O, von Jagow-Westermann B, Stukowski B. Kinetic and regulatory properties of heart muscle pyruvate dehydrogenase. Z Physiol Chem 350:329-334, 1969.
66. Whitehouse S, Randle PJ. Activation of pyruvate dehydrogenase in perfused rat heart by dichloroacetate. Biochem J 134:651-653, 1973.
67. Guder WG, Wieland OH. Metabolism of isolated kidney tubules. Regulation of pyruvate dehydrogenase by metabolic substrates. Eur J Biochem 42:529-538, 1974.
68. Halestrap AP, Denton RM. The specificity and metabolic implications of the inhibition of pyruvate transport in isolated mitochondria and intact tissue preparations by alpha-Cyano-4-hydroxycinnamate and related compounds. Biochem J 148:97-106, 1975.
69. Halestrap AP. The mitochondrial pyruvate carrier. Kinetics and specificity for substrates and inhibitors. Biochem J 148:85-96, 1975.
70. Hiltunen JK, Hassinen IE. Energy-linked regulation of glucose and pyruvate oxidation in isolated perfused rat heart. Role of py. Biochim Biophys Acta 440:377-390, 1976.
71. Halestrap AP. Transport of pyruvate and lactate into human erythrocytes. Biochem J 156:193-207, 1976.
72. Randle PJ. Regulation of glycolysis and pyruvate oxidation in cardiac muscle. Circ Res 38:8-15, 1976.
73. Mullhofer G, Muller C, Von Stetten C, Gruber E. Carbon-14 tracer studies in the metabolism of isolated rat-liver parenchymal cells under conditions of gluconeogenesis from lactate and pyruvate. Eur J Biochem 75:331-341, 1977. (Pubitemid 8119160)
74. Hansford RG. Studies on inactivation of pyruvate dehydrogenase by palmitoylcarnitine oxidation in isolated rat he. J Biol Chem 25:1552-1560, 1977. (Pubitemid 8062349)
75. Mullhofer G, Schwab A, Muller C, Von Stetten C, Gruber E. Carbon-14 tracer studies in rat-liver perfusion experiments under conditions of gluconeogenesis from lactate and pyruvate. Eur J Biochem 75:319-330, 1977. (Pubitemid 8119159)
76. Scholz R, Olson MS, Schwab AJ, Schwabe U, Noell C, Braun W. The effect of fatty acids on the regulation of pyruvate dehydrogenase in perfused rat liver. Eur J Biochem 86:519-530, 1978. (Pubitemid 8340081)
77. Halestrap AP, Scott RD, Thomas AP. Mitochondrial pyruvate transport and its hormonal regulation. Int J Biochem 11:97-105, 1979.
78. Peuhkurinen KJ, Nuutinen EM, Pietilainen EP, Hiltunen JK, Hassinen IE. Role of pyruvate carboxylation in the energy-linked regulation of pool sizes of tricarboxylic acid-cycle intermediates in the myocardium. Biochem J 208:577-581, 1982.
79. Peuhkurinen KJ, Hassinen IE. Pyruvate carboxylation as an anaplerotic mechanism in the isolated perfused rat heart. Biochem J 202:67-76, 1982.
80. Schoolwerth AC, LaNoue KF. Transport of metabolic substrates in renal mitochondria. Annu Rev Physiol 47:143-171, 1985. (Pubitemid 15142376)
81. Poole RC, Cranmer SL, Halestrap AP, Levi AJ. Substrate and inhibitor specificity of monocarboxylate transport into heart cells and erythrocytes. Further evidence for the existence of two distinct carriers. Biochem J 269:827-829, 1990.
82. Poole RC, Halestrap AP. Transport of lactate and other monocarboxylates across mammalian plasma membranes. Am J Physiol 264:C761-782, 1993.
83. Laughlin MR, Taylor J, Chesnick AS, DeGroot M, Balaban RS. Pyruvate and lactate metabolism in the in vivo dog heart. Am J Physiol 264:H2068-2079, 1993.
84. Halestrap AP, Price NT. The proton-linked monocarboxylate transporter (MCT) family: structure, function and regulation. Biochem J 343 Pt 2:281-299, 1999.
85. Ardenkjaer-Larsen JH, Fridlund B, Gram A, Hansson G, Hansson L, Lerche MH, Servin R, Thaning M, Golman K. Increase in signal-tonoise ratio of > 10,000 times in liquid-state NMR. Proc Natl Acad Sci U S A 100:10158-10163, 2003. (Pubitemid 37071849)
86. Golman K, Zandt RI, Lerche M, Pehrson R, Ardenkjaer-Larsen JH. Metabolic imaging by hyperpolarized 13C magnetic resonance imaging for in vivo tumor diagnosis. Cancer Res 66:10855-10860, 2006. (Pubitemid 44876982)
87. Kingsley-Hickman P, Sako E, Mohanakrishnan P, Robitaille P, From A, Foker J, Ugurbil K. 31P NMR studies of ATP synthesis and hydrolysis kinetics in the intact myocardium. Biochemistry 26:7501-7510, 1987.
88. Bassenge E, Sommer O, Schwemmer M, Bunger R. Antioxidant pyruvate inhibits cardiac formation of reactive oxygen species through changes in redox state. Am J Physiol Heart Circ Physiol 279:H2431-2438, 2000.
89. LaNoue KF, Schoolwerth AC. Metabolite transport in mitochondria. Annu Rev Biochem 48:871-922, 1979.
90. Poole RC, Halestrap AP, Price SJ, Levi AJ. The kinetics of transport of lactate and pyruvate into isolated cardiac myocytes from guinea pig. Kinetic evidence for the presence of a carrier distinct from that in erythrocytes and hepatocytes. Biochem J 264:409-418, 1989.
91. Wang X, Poole RC, Halestrap AP, Levi AJ. Characterization of the inhibition by stilbene disulphonates and phloretin of lactate and pyruvate transport into rat and guinea-pig cardiac myocytes suggests the presence of two kinetically distinct carriers in heart cells. Biochem J 290 (Pt 1):249-258, 1993. (Pubitemid 23081226)
92. Agius L, Alberti KG. Regulation of flux through pyruvate dehydrogenase and pyruvate carboxylase in rat hepatocytes. Effects of fatty acids and glucagon. Eur J Biochem 152:699-707, 1985. (Pubitemid 16192376)
93. Merritt ME, Harrison C, Storey C, Jeffrey FM, Sherry AD, Malloy CR. Hyperpolarized 13C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci U S A 104:19773-19777, 2007.
94. Taegtmeyer H. On the inability of ketone bodies to serve as the only energy providing substrate for rat heart at physiological work load. Basic Res Cardiol 78:435-450, 1983.
95. Kauppinen RA, Hiltunen JK, Hassinen IE. Subcellular distribution of phosphagens in isolated perfused rat heart. FEBS Lett 112:273-276, 1980. (Pubitemid 10092417)
96. Hermann HP, Pieske B, Schwarzmuller E, Keul J, Just H, Hasenfuss G. Haemodynamic effects of intracoronary pyruvate in patients with congestive heart failure: an open study. Lancet 353:1321-1323, 1999. (Pubitemid 29178783)
97. Hasenfuss G, Maier LS, Hermann HP, Luers C, Hunlich M, Zeitz O, Janssen PM, Pieske B. Influence of pyruvate on contractile performance and Ca(2+) cycling in isolated failing human myocardium. Circulation 105:194-199, 2002. (Pubitemid 34084318)
98. Hermann HP, Arp J, Pieske B, Kogler H, Baron S, Janssen PM, Hasenfuss G. Improved systolic and diastolic myocardial function with intracoronary pyruvate in patients with congestive heart failure. Eur J Heart Fail 6:213-218, 2004. (Pubitemid 38249365)
99. Mongan PD, Fontana JL, Chen R, Bunger R. Intravenous pyruvate prolongs survival during hemorrhagic shock in swine. Am J Physiol 277:H2253-2263, 1999. (Pubitemid 30048145)
100. Mongan PD, Capacchione J, Fontana JL, West S, Bunger R. Pyruvate improves cerebral metabolism during hemorrhagic shock. Am J Physiol Heart Circ Physiol 281:H854-864, 2001. (Pubitemid 32756112)
101. Schmitz E. Einfluss von Pyruvat auf eine experimentell induzierte Herzinsuffizienz am Hund. Library of Ludwig-Maximilians, University of Munich, Germany. 1987.
102. Schroeder MA, Cochlin LE, Heather LC, Kieran Clarke K, Radda GK, Tyler DJ. In vivo assessment of pyruvate dehydrogenase flux in the heart using hyperpolarized carbon-13 magnetic resonance Proc Natl Acad Sci U S A 105:12051-12056, 2008.